TrialsgrambetaRCTs are beautiful

ECLS-SHOCK

2023

Extracorporeal Life Support in Infarct-Related Cardiogenic Shock

In 420 patients with acute MI complicated by cardiogenic shock, VA-ECMO did not reduce 30-day mortality versus standard care, with more bleeding and vascular complications.

Result

Efficacy: 30-day all-cause mortalityRR 0.98 (95% CI 0.80-1.19) · P = 0.81

Below 1 favours VA-ECMO, above 1 favours standard care.

Event rates
Absolute difference
1.2 points

The absolute difference is derived from the event rates.

Also reported: BARC 3–5 bleeding 23.4% vs 9.6%. 1-y mortality 55.0% vs 55.8%.

Original publication
Subtopic
Mechanical support
Design
Multicentre RCT, Germany/Slovenia
Relevance
Important: one of several pillars.
Source
Thiele H, et al. N Engl J Med. 2023;389(14):1286-1297.doi 10.1056/NEJMoa2307227

Discussion & critique

Largest VA-ECMO trial; no benefit and clear bleeding harm. Reserve VA-ECMO for refractory biventricular failure.

Discussed in podcasts